R44TR004250

High-throughput human micro-heart muscle for drug discovery - Although heart failure is the leading cause of death in the U.S., therapeutic treatments remain suboptimal as the pharmaceutical industry has proven incapable of generating more predictive human-relevant preclinical models of the human heart that are amenable to high-throughput screening (HTS) assays. Thus, vast compound libraries remain virtually unexplored in an effective manner, hindering the speedy development of new therapeutic approaches to treat heart disease.

Organos, Inc. proposes a solution to this problem in the commercial development of an in vitro miniaturized array of "micro-heart muscle" (ΜHM) amenable to HTS. Organos' innovation is that our HTS capable assay is based on heart muscle contraction metrics, which to date has neither been achieved nor is attainable in two-dimensional (2D) platforms.

A main focus of this proposal is to create an HTS assay, using ΜHMs that fit a 384 microplate form factor, amenable to use with pre-existing automation. In the ΜHM, elongated muscle fibers are formed from induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in polymer templates that promote uniaxial alignment and contraction, robust sarcomere assembly, and physiologically relevant drug responsiveness.

The ΜHM 384 HTS platform and assay will lead the front end of Organos' discovery pipeline and feed data into our computational and deep learning models for compound discovery, target identification, and repurposing. The specific aims focus first on the fabrication of the HTS ΜHM platform, microtissue characterization, and assay development, then on validation and its use in HTS to identify compounds that improve cardiac contractility.

The main outcome will be a robust HTS assay employing human heart muscle suitable for use in large screening campaigns for de novo drug discovery.

Organos

NOT APPLICABLE

93.350 - National Center for Advancing Translational Sciences

National Center for Advancing Translational Sciences (NCATS) [HHS - NIH]

Berkeley, California 947022471 United States

Single Zip Code

PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) (PA-24-245)

Amendment Since initial award the End Date has been extended from 05/31/24 to 06/30/27 and the total obligations have increased 383% from $622,880 to $3,009,189.